Mitchell A. Katz

Pharmacokinetics of an Immediate‐Release Oral Formulation of Fampridine (4‐Aminopyridine) in Normal Subjects and Patients with Spinal Cord Injury

Keith C. Hayes, Mitchell A. Katz, John Devane et al. · The Journal of Clinical Pharmacology · 2003 · 75 citations

Pharmacokinetics and safety of multiple oral doses of sustained-release 4-aminopyridine (fampridine-sr) in subjects with chronic, incomplete spinal cord injury 11A commercial party with a direct financial interest in the results of the research supporting this article has conferred or will confer a financial benefit on the author or 1 or more of the authors.

Keith C. Hayes, Patrick J. Potter, Jane Hsieh et al. · Archives of Physical Medicine and Rehabilitation · 2003 · 40 citations

Financial Benefit, Spinal Cord Injury, Direct Financial Interest +9

Pharmacokinetic Studies of Single and Multiple Oral Doses of Fampridine-SR (Sustained-Release 4-Aminopyridine) in Patients With Chronic Spinal Cord Injury

Keith C. Hayes, Patrick J. Potter, Robert R. Hansebout et al. · Clinical Neuropharmacology · 2003 · 18 citations

Comparison of an enzyme-linked immunosorbent assay with radioimmunoassay for the measurement of pneumococcal capsular polysaccharide antibodies

Mitchell A. Katz, Gerald Schiffman · Molecular Immunology · 1985 · 11 citations

Immunocytochemical Technique, Bioanalysis, Immunology +5

A comparison of antibody concentration measured by mouse protection assay and radioimmunoassay in sera from patients at high risk of developing pneumococcal disease

Mitchell A. Katz, Sheldon H. Landesman, Gerald Schiffman · Molecular Immunology · 1984 · 11 citations

Antibody Concentration, Mouse Protection Assay, Immunodeficiencies +10